|
25 Companies |
|
52 Products |
|
52 Products |
|
12 Mechanisms of Action |
|
0 Trials |
|
119 News |
|
| 123» |
- | Yervoy (ipilimumab) / Ono Pharma, BMS
Phase classification, Combination therapy: Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) - Jan 24, 2024
P1, N=3, Terminated, Sponsor: Stanford University
Phase classification: P1/2 --> P1
- | Hu-Mik-Beta-1 / National Institute of Neurological Disorders and Stroke
Trial completion date: Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov) - Jan 11, 2019
P1, N=9, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P1/2 --> P1 Trial completion date: Nov 2010 --> Jan 2019
- | Trial completion, Trial completion date, Trial primary completion date: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=2545, Completed, Sponsor: Children's Oncology Group
Trial completion date: Nov 2010 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018
- | Trial completion, Biopsy: Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=83, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed | Trial completion date: Jan 2100 --> Jun 2018 | Trial primary completion date: Jan 2100 --> Jun 2018 Recruiting --> Completed
- | Trial completion, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=80, Completed, Sponsor: Wake Forest University Health Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial completion, Enrollment change, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 11, 2018
P1, N=34, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=60 --> 34
- | Trial completion: Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant (clinicaltrials.gov) - Feb 1, 2018
P=N/A, N=304, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed | N=60 --> 34 Active, not recruiting --> Completed
- | Enrollment closed: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=3000, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | lenalidomide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (clinicaltrials.gov) - Sep 25, 2017
P1, N=17, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Dec 2016 --> Nov 2012
- | Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 18, 2017
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Dec 2016 --> Nov 2012 Trial primary completion date: Dec 2016 --> Dec 2017
- | dapsone / Generic mfg.
Enrollment change: Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=41, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2016 --> Dec 2017 N=200 --> 41
- | Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date: Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia (clinicaltrials.gov) - Apr 7, 2017
P2, N=25, Terminated, Sponsor: National Cancer Institute (NCI)
N=200 --> 41 Trial primary completion date: Apr 2009 --> May 2007
- fludarabine IV / Generic mfg.
Enrollment change, Trial termination: Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov) - Aug 11, 2016
P2, N=12, Terminated, Sponsor: German CLL Study Group
Trial primary completion date: Apr 2009 --> May 2007 N=30 --> 12 | Recruiting --> Terminated; slow recruitment
- Campath (alemtuzumab) / Sanofi
Trial completion: Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia (clinicaltrials.gov) - Aug 11, 2016
P2, N=17, Completed, Sponsor: German CLL Study Group
N=30 --> 12 | Recruiting --> Terminated; slow recruitment Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jul 14, 2016
P2, N=0, Withdrawn, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Completed N=38 --> 0 | Suspended --> Withdrawn
- | cyclosporine / Generic mfg.
Trial completion: Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer (clinicaltrials.gov) - Jul 4, 2016
P2, N=30, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=38 --> 0 | Suspended --> Withdrawn Recruiting --> Completed
- | ondansetron / Generic mfg.
Trial completion, Metastases: Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment (clinicaltrials.gov) - Jul 4, 2016
P3, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Dec 21, 2015
P2, N=14, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Dec 6, 2015
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- bortezomib / Generic mfg., everolimus / Generic mfg.
Trial termination, Trial primary completion date: Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov) - Oct 28, 2015
P1, N=30, Terminated, Sponsor: Brian Hill, MD, PhD
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Oct 2015; Treatment ineffective
- | ontuxizumab (MORAb-004) / Eisai
Trial completion, Enrollment change: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Sep 18, 2015
P1, N=27, Completed, Sponsor: Morphotek
Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Oct 2015; Treatment ineffective Active, not recruiting --> Completed | N=65 --> 27
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=5, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=65 --> 27 Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Enrollment closed, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Aug 19, 2015
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014 Recruiting --> Active, not recruiting
- Trial primary completion date, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2011 --> Feb 2012
- busulfan / Generic mfg.
Trial completion, Trial primary completion date: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Aug 13, 2015
P0, N=33, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Oct 2011 --> Feb 2012 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2015
- cyclosporine / Generic mfg.
Trial termination: Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia (clinicaltrials.gov) - Jul 21, 2015
P2, N=5, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2015 Completed --> Terminated; Study terminated due to low accrual and the investigator left the NIH.
- dasatinib / Generic mfg.
Trial completion, Surgery, Metastases: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 26, 2015
P1, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Study terminated due to low accrual and the investigator left the NIH. Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Dec 2015
- Trial withdrawal: Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=0, Withdrawn, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Apr 2015 --> Dec 2015 Terminated --> Withdrawn
- dasatinib / Generic mfg.
Enrollment change, Surgery, Metastases: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 3, 2015
P1, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Withdrawn N=42 --> 80
- peripheral blood stem cell transplantation / National Cancer Institute
Enrollment change, Trial withdrawal, Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - May 7, 2015
P=N/A, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center
N=42 --> 80 N=13 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion: Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 26, 2015
P1, N=25, Completed, Sponsor: National Cancer Institute (NCI)
N=13 --> 0 | Not yet recruiting --> Withdrawn No longer recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Apr 14, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
No longer recruiting --> Completed Trial primary completion date: Mar 2015 --> Sep 2015
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 19, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Mar 2014 --> Mar 2015
- busulfan / Generic mfg.
Enrollment closed, Trial primary completion date: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Feb 2, 2015
P0, N=30, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015
- bortezomib / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov) - Jan 26, 2015
P1, N=36, Recruiting, Sponsor: Brian Hill, MD, PhD
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Jan 2015 --> Jun 2015
- || ontuxizumab (MORAb-004) / Eisai
Enrollment closed: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 12, 2015
P1, N=65, Active, not recruiting, Sponsor: Morphotek
Trial primary completion date: Jan 2015 --> Jun 2015 Recruiting --> Active, not recruiting
- || ontuxizumab (MORAb-004) / Eisai
Trial initiation date: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Dec 19, 2014
P1, N=65, Recruiting, Sponsor: Morphotek
Recruiting --> Active, not recruiting Initiation date: Aug 2013 --> Nov 2013
- peripheral blood stem cell transplantation / National Cancer Institute
Trial initiation date, Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Aug 2013 --> Nov 2013 Initiation date: Oct 2014 --> Feb 2015
- | Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Phase classification: Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy (clinicaltrials.gov) - Oct 17, 2014
P2, N=320, Completed, Sponsor: Mayo Clinic
Initiation date: Oct 2014 --> Feb 2015 Phase classification: P=N/A --> P2
- | Cilcane (cilengitide) / Iceni Pharma
Trial completion, Metastases: EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - Sep 17, 2014
P1, N=40, Completed, Sponsor: Indiana University School of Medicine
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- | Trial completion: American Ginseng in Treating Patients With Fatigue Caused by Cancer (clinicaltrials.gov) - Aug 6, 2014
P3, N=364, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- bortezomib / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov) - Jul 23, 2014
P1, N=36, Recruiting, Sponsor: Brian Hill, MD, PhD
Active, not recruiting --> Completed Trial primary completion date: Nov 2013 --> Jan 2015
- dasatinib / Generic mfg.
Enrollment closed, Surgery, Metastases: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 2, 2014
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2013 --> Jan 2015 Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - May 26, 2014
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Apr 2015
- MK-2206 / Merck (MSD)
Enrollment change: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) - Apr 27, 2014
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Apr 2015 N=96 --> 45
- busulfan / Generic mfg.
Enrollment open: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Mar 17, 2014
P0, N=30, Recruiting, Sponsor: Case Comprehensive Cancer Center
N=96 --> 45 Not yet recruiting --> Recruiting
- Fodosine (forodesine) / Mundipharma, BioCryst
Trial completion: BCX-1777 in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: BioCryst Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion, Metastases: Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (clinicaltrials.gov) - Feb 22, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed